Pulmonary Arterial Hypertension (PAH) Therapeutics – Global Drug Forecasts and Treatment Analysis to 2020
GlobalData estimated the global Pulmonary Arterial Hypertension (PAH) therapeutics market to be worth $3.3 billion in 2011. This estimate represents the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China, India and Russia, collectively. Between 2002 and 2011, the global PAH therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 38.6%. PAH is a rare indication, yet despite its small patient volume, the PAH therapeutics market showed tremendous growth in the historic period. This growth was due...
View full press release